Neurological Biomarker Market

Neurological Biomarker Market by Types (Proteomic, Imaging, Genomic, Metabolomics, and Others), Applications (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), End-users (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1432
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 184
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global neurological biomarkers market size is estimated to record a considerable CAGR during the forecast period, 2021–2028. The rising market is owing to the increasing in nervous disorder as well as the growing awareness on the neurological disease detection and treatment.

Neurological Biomarker Market Key Takeaways

Neurological biomarkers refer to the molecules in the blood or cerebral spinal fluid (CSF) that assist the prognosis of mind issues and display ailment progression. The fundamental reasserts biomarkers are genetic metabolite levels, mutations, mind imaging and adjustments in protein expression. As they discover organic responses to experimental capsules and resource in coming across new goals for healing intervention, neurological biomarkers are broadly utilized in scientific exercise throughout drug development. At present, researchers’ degree biomarker concentrations to offer non-invasive testing, in advance prognosis, and personalized treatments.

According to World Health Organization (WHO), globally more than 300 million people were suffering from clinical depression in 2018. As per the estimation of École des Neurosciences de Paris Île-de-France, over 6 million people are dying caused by stroke every year and the mortality rate is close to 80% in low and middle income countries. Over 600 neurological diseases have been discovered that can affect the nerves, brain, and spine in human’s body, which lead to the leading causes of several neurological disorders. Some of the examples of neuro-disorders are such as Alzheimer’s disease, brain tumors, cerebral stroke, epilepsy and Parkinson’s disease.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing cases of neurological disorders such as stroke, motor neuron disease, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease especially in developed countries are fueling the biomarkers’ market growth.
  • Largely adoption of minimally invasive procedures and personalized medicines are driving the market growth.
  • Rising number of clinical trials and advent of digital biomarkers are anticipated to propel the market expansion during the forecast period.
  • Less awareness of neurological diseases and lack of treatment facilities in low income countries are the factors hampering the market growth.
  • High cost involved in neuro- research & development affects the market share in low & middle income level countries. This is expected to hamper the market growth in the coming years.

Scope of the Report

The report on the global neurological biomarker market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Neurological Biomarker Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Proteomic, Imaging, Genomic, Metabolomics, and Others), Applications (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), End-users  (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, Inc.; and Alseres Pharmaceuticals, Inc.

 

Market Segment Insights

Genomic segment is expected to dominate the market

Based on types, the neurological biomarkers market is categorized as proteomic, imaging, genomic, metabolomics, and others. The genomic segment is expected to dominate the market during the forecast period owing to increasing adoption of advanced technology for genomic research and increasing awareness of the biomarker type. Moreover, rising shift of diagnostic paradigm towards the advancement of gene evaluation and genetic counselling pave a key aspect for the segment growth. Genomic biomarkers are directing towards neurological exercise regarding personalized technique primarily based on patient’s character genetic specifications and predispositions. On the other hand, the imaging segment is projected to hold a large market share during the forecast period due to the aid of using considerable R&D in neuroscience and technological improvements, which have enabled visualization of abnormalities in the body.

Alzheimer’s disease segment is projected to expand at a considerable market

Based on the applications, the market is divided into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, autism spectrum disorders, and others. The Alzheimer’s disease segment is projected to expand at a considerable market share in the coming years as wide prevalence of the disease in many developed countries and wide adoption of neurological biomarkers for the treatment of the disease. Amyloid-β, general tau, and phosphorylated tau are the important cerebrospinal fluid biomarkers that are widely adopted for reflecting the pathophysiology of this disease. Identification of those biomarkers with in the initial levels of the disorder can assist in timely treatment.

Meanwhile, the Parkinson’s disease segment is anticipated to exhibit a healthy CAGR during the projected period due to the emerging disruptive studies and trials ongoing for advanced diagnostics of Parkinson’s disorder. Earlier, protein biomarkers, amino acids, and dopamine metabolites had been the high analytical gear for diagnosing Parkinson’s disorder. Moreover, numerous novel applicants are volunteering for the disease research purpose by diagnostic biomarkers, which is expected to boost the segment growth.

Neurological Biomarker Market by applications

Hospital laboratories segment is anticipated to gain a large market share

On the basis of end-users, the neurological biomarkers market is segmented into independent clinical diagnostic centers, hospital laboratories, research organizations, and others. The hospital laboratories segment is anticipated to gain a substantial market share during the forecast period. The segment growth can be attributed to growing affected person influx for most cancers prognosis in hospitals, developing patron awareness, and growing investments in healthcare infrastructure in growing and underdeveloped countries. On the other hand, the research organizations segment is expected to grow at a considerable rate during the forecast period attributing to the huge investments for neuroscience research worldwide. For example, the NINDS Human Biomarkers Biospecimen and Data Repository is dedicated to advanced research and determination of neurological biomarkers.

North America is estimated to dominate the market

In terms of regions, the global neurological biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to dominate the market during the forecast period due to evident business trend of neurological diagnostics in the region especially in the U.S. Some of the other factors fueling the market growth include proactive government initiatives, rising expenditure in healthcare infrastructure, and local presence of major manufacturers in the region.

The market of Asia Pacific, on the other hand, is expected to expand rapidly during the forecast period. The regional growth rate is anticipated to be influenced by overall economic development, improvements in healthcare infrastructure, increased personal disposable income, and rising consumer awareness. Emerging economies such as China, India, and South Korea are encouraging a wide scale development programs and research for biomarkers, which are likely to boost the regional market expansion in the coming years.

Neurological Biomarker Market by Regions

Segments

Segments Covered in the Report
The global neurological biomarker market has been segmented on the basis of

Types

  • Proteomic
  • Imaging
  • Genomic
  • Metabolomics
  • Others

Applications

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Abbott
  • QIAGEN
  • Myriad RBM
  • Thermo Fisher Scientific Inc.
  • Athena Diagnostics
  • Bio-Rad Laboratories, Inc.
  • AbaStar MDx, Inc.
  • Acumen Pharmaceuticals
  • Banyan Biomarkers, Inc.
  • Alseres Pharmaceuticals, Inc.

Competitive Landscape

Some of the major players competing in the market are Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, Inc.; and Alseres Pharmaceuticals, Inc.

To expand their market reach, major market players are indulged in innovation and development of new products. Market players are stepping into merger & acquisitions, licensing partnerships, and co-development to stay ahead in the market competition. For example, Abbott acquired Alere Inc. in September 2017, which was expected to help the company to expand the point of care division into business portfolio.

Neurological Biomarker Market by Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neurological Biomarker Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Neurological Biomarker Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Neurological Biomarker Market - Supply Chain
  4.5. Global Neurological Biomarker Market Forecast
     4.5.1. Neurological Biomarker Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Neurological Biomarker Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Neurological Biomarker Market Absolute $ Opportunity
5. Global Neurological Biomarker Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Neurological Biomarker Market Size and Volume Forecast by Types
     5.3.1. Proteomic
     5.3.2. Imaging
     5.3.3. Genomic
     5.3.4. Metabolomics
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Neurological Biomarker Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Neurological Biomarker Market Size and Volume Forecast by Applications
     6.3.1. Alzheimer’s Disease
     6.3.2. Parkinson’s Disease
     6.3.3. Multiple Sclerosis
     6.3.4. Autism Spectrum Disorders
     6.3.5. Others
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Neurological Biomarker Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Neurological Biomarker Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Neurological Biomarker Demand Share Forecast, 2019-2026
8. North America Neurological Biomarker Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Neurological Biomarker Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Neurological Biomarker Market Size and Volume Forecast by Types
     8.4.1. Proteomic
     8.4.2. Imaging
     8.4.3. Genomic
     8.4.4. Metabolomics
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Neurological Biomarker Market Size and Volume Forecast by Applications
     8.7.1. Alzheimer’s Disease
     8.7.2. Parkinson’s Disease
     8.7.3. Multiple Sclerosis
     8.7.4. Autism Spectrum Disorders
     8.7.5. Others
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Neurological Biomarker Demand Share Forecast, 2019-2026
9. Latin America Neurological Biomarker Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Neurological Biomarker Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Neurological Biomarker Market Size and Volume Forecast by Types
     9.4.1. Proteomic
     9.4.2. Imaging
     9.4.3. Genomic
     9.4.4. Metabolomics
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Neurological Biomarker Market Size and Volume Forecast by Applications
     9.7.1. Alzheimer’s Disease
     9.7.2. Parkinson’s Disease
     9.7.3. Multiple Sclerosis
     9.7.4. Autism Spectrum Disorders
     9.7.5. Others
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Neurological Biomarker Demand Share Forecast, 2019-2026
10. Europe Neurological Biomarker Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Neurological Biomarker Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Neurological Biomarker Market Size and Volume Forecast by Types
     10.4.1. Proteomic
     10.4.2. Imaging
     10.4.3. Genomic
     10.4.4. Metabolomics
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Neurological Biomarker Market Size and Volume Forecast by Applications
     10.7.1. Alzheimer’s Disease
     10.7.2. Parkinson’s Disease
     10.7.3. Multiple Sclerosis
     10.7.4. Autism Spectrum Disorders
     10.7.5. Others
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Neurological Biomarker Demand Share Forecast, 2019-2026
11. Asia Pacific Neurological Biomarker Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Types
     11.4.1. Proteomic
     11.4.2. Imaging
     11.4.3. Genomic
     11.4.4. Metabolomics
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Neurological Biomarker Market Size and Volume Forecast by Applications
     11.7.1. Alzheimer’s Disease
     11.7.2. Parkinson’s Disease
     11.7.3. Multiple Sclerosis
     11.7.4. Autism Spectrum Disorders
     11.7.5. Others
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Neurological Biomarker Demand Share Forecast, 2019-2026
12. Middle East & Africa Neurological Biomarker Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Types
     12.4.1. Proteomic
     12.4.2. Imaging
     12.4.3. Genomic
     12.4.4. Metabolomics
     12.4.5. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Neurological Biomarker Market Size and Volume Forecast by Applications
     12.7.1. Alzheimer’s Disease
     12.7.2. Parkinson’s Disease
     12.7.3. Multiple Sclerosis
     12.7.4. Autism Spectrum Disorders
     12.7.5. Others
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Neurological Biomarker Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Neurological Biomarker Market: Market Share Analysis
  13.2. Neurological Biomarker Distributors and Customers
  13.3. Neurological Biomarker Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report
The global neurological biomarker market has been segmented on the basis of

Types

  • Proteomic
  • Imaging
  • Genomic
  • Metabolomics
  • Others

Applications

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Abbott
  • QIAGEN
  • Myriad RBM
  • Thermo Fisher Scientific Inc.
  • Athena Diagnostics
  • Bio-Rad Laboratories, Inc.
  • AbaStar MDx, Inc.
  • Acumen Pharmaceuticals
  • Banyan Biomarkers, Inc.
  • Alseres Pharmaceuticals, Inc.

Some of the major players competing in the market are Abbott; QIAGEN; Myriad RBM; Thermo Fisher Scientific Inc.; Athena Diagnostics; Bio-Rad Laboratories, Inc.; AbaStar MDx, Inc.; Acumen Pharmaceuticals; BANYAN BIOMARKERS, Inc.; and Alseres Pharmaceuticals, Inc.

To expand their market reach, major market players are indulged in innovation and development of new products. Market players are stepping into merger & acquisitions, licensing partnerships, and co-development to stay ahead in the market competition. For example, Abbott acquired Alere Inc. in September 2017, which was expected to help the company to expand the point of care division into business portfolio.

Neurological Biomarker Market by Key Players

Buy Report